{"id":819122,"date":"2025-02-27T08:09:06","date_gmt":"2025-02-27T13:09:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/"},"modified":"2025-02-27T08:09:06","modified_gmt":"2025-02-27T13:09:06","slug":"cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/","title":{"rendered":"CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif., Feb.  27, 2025  (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report full year 2024 financial results on Thursday, March 6, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at\u00a05:00 p.m. ET\u00a0\/\u00a02:00 p.m. PT.<\/p>\n<p align=\"justify\">Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4fkPWYYhPJsdVpynPo6kgxhye7W_qkmAPKnKROUNNq4awAcefdgPWemmWfq0zHOZ9jS9le6hBJvuYVddrZfSvIl0kEt2VPzx7bfY46LHND7T6FYqT9rNOQhRfj9_7JJpW8mn3aMTQW9BRdN_b8EhfHW_5MtaTDzE_Ih9wbQgEos=\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.cytomx.com\/events-and-presentations<\/a>. Participants may register for the conference call <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aexf7uDXkTmwY1BHqwXfYBdjr-jVrZ0m4jOobyCXM_88ikdyM0w_m0DcrmdonvlaRP2_t9yh5WoddN6xIo2tN707Wtavkm_uvtHKzZeHt4wUCEwNKhuBLS2l05KTE5E5NA3eEEXGx_k4hNEqAgcV2Q==\" rel=\"nofollow\" target=\"_blank\">here<\/a> and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company\u2019s website.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0CytomX Therapeutics, Inc.<\/strong><br \/>\n        <br \/>CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY\u00ae therapeutic platform, CytomX\u2019s vision is to create safer, more effective therapies for the treatment of cancer. CytomX\u2019s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (\u201cADCs\u201d), T-cell engagers, and immune modulators such as cytokines. CytomX\u2019s clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) and armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers, including CRC, and was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. CX-904 is partnered with Amgen in a global co-development alliance. CX-801 is a masked interferon alpha-2b PROBODY\u00ae cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xh-v-phcZrFbbPhLORDhm70foswPr8Opi6qVIqyCYBVxP6Qmdmmgj59HZfp2fuhBYPA0k2vugqSJjz1c9KoZltrpNm7sdfGTUgGLMxD3aaemZlTGL-6yNm5gj5zRhZ3p027A_MBNSJ4CnwLLgPLO6Vv0s8iHFgNHY1Ra_lIMVElVFd2r4V32AmeNa8kHW3eHu4_3VzTEu9HzPhFp8trB3JLJ5GwICZUNVytk4D8hidE=\" rel=\"nofollow\" target=\"_blank\"><strong>www.cytomx.com<\/strong><\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2VCyqgRo-LdI90A_6UvYFWZX0xHE0zd52pWaQYWDqHLrIc7zOpp0aGel4FZW5Q4RnjXtT9GOLh3tQTn7-eXFTjrUIPAaIuC5t4U-36ZjofD7Rdfm0cAYZMWt-P0NJzjfK3zljG4eU_Qy1AWJqdAH4N06zIiYYmPkHcX3JtdP1KSW0tqWY3M8r4zWyOoXiLTeA6lYDMdpVGK5lETJ2Aua2azpf7n_IP0Sz8wZuDld4BmSIsPzc_NHV-cN1O4napKeRrADU16-7a9k9p-2cCVCzg==\" rel=\"nofollow\" target=\"_blank\"><strong>LinkedIn<\/strong><\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JRwv8OWUWcyOCCWupKP6EZ1niseFE6nGHKh8d5FWm6D4lwHxcsiytKq1XtAEumg2W73LG0zDrWk2mhsfBrzlBlN8InlkkSGTIMG0J7DnTIqeGdf4NKPfKAwoSs9BLKur2548vZBDeM0uURpoCdL1voZFn2QsOnWEHSP5YdbiOiTpJI1jz8isn7GwciXXcUcXoINS3anRpIQZ4byXZES6rUFtyUz263iqubI_Oley-6M=\" rel=\"nofollow\" target=\"_blank\"><strong>X<\/strong><\/a><strong> (formerly Twitter)<\/strong>.<\/p>\n<p align=\"justify\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>Chris Ogden<br \/>SVP, Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9nqJ27CGuLRZinlLhKXYNvzADFGIAFWemebjCbKESHHSj23T17Ib9IFAu4OI54_CNXGNWG1q9mqwnZFrPvzLLwsrRMl9hNns1pS5X3Sv740=\" rel=\"nofollow\" target=\"_blank\">cogden@cytomx.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Precision AQ (formerly Stern Investor Relations)<br \/>Stephanie Ascher<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=m5sD5CumsUfO7F1vQI_pY00yX6NA7uoIqcUbG7eKwBOvAHeBUn2_VgN5jXm6S2b0xhHEkjx8c2-PUl1Yzd9eTBFo78ev0ToLu0H--sPg7pWHbvDuKgi131OwbqBASriV\" rel=\"nofollow\" target=\"_blank\">stephanie.ascher@precisionaq.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Redhouse Communications<br \/>Teri Dahlman<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HjdV-DEnAX_C_FqcdZy6LtWpqZt2MyeeEFJywdqpcgNRTF28GaSjw-t3db6WQSOxmU6sPrLm3edokFskqQqMHTVTHnXo29czaF-8oY32XJE=\" rel=\"nofollow\" target=\"_blank\">teri@redhousecomms.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTQ5OSM2NzgwOTk1IzIwMjAyMjc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjZlYjBjNzctZDViMS00NDBjLWE3ZjYtMzBiNmQxMDc0OWU0LTEwMzE3OTk=\/tiny\/CytomX-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report full year 2024 financial results on Thursday, March 6, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at\u00a05:00 p.m. ET\u00a0\/\u00a02:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX\u2019s website at\u00a0https:\/\/ir.cytomx.com\/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-819122","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report full year 2024 financial results on Thursday, March 6, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at\u00a05:00 p.m. ET\u00a0\/\u00a02:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX\u2019s website at\u00a0https:\/\/ir.cytomx.com\/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company\u2019s &hellip; Continue reading &quot;CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-27T13:09:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTQ5OSM2NzgwOTk1IzIwMjAyMjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025\",\"datePublished\":\"2025-02-27T13:09:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/\"},\"wordCount\":417,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NTQ5OSM2NzgwOTk1IzIwMjAyMjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/\",\"name\":\"CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NTQ5OSM2NzgwOTk1IzIwMjAyMjc=\",\"datePublished\":\"2025-02-27T13:09:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NTQ5OSM2NzgwOTk1IzIwMjAyMjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NTQ5OSM2NzgwOTk1IzIwMjAyMjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/","og_locale":"en_US","og_type":"article","og_title":"CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report full year 2024 financial results on Thursday, March 6, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at\u00a05:00 p.m. ET\u00a0\/\u00a02:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX\u2019s website at\u00a0https:\/\/ir.cytomx.com\/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company\u2019s &hellip; Continue reading \"CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-27T13:09:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTQ5OSM2NzgwOTk1IzIwMjAyMjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025","datePublished":"2025-02-27T13:09:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/"},"wordCount":417,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTQ5OSM2NzgwOTk1IzIwMjAyMjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/","name":"CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTQ5OSM2NzgwOTk1IzIwMjAyMjc=","datePublished":"2025-02-27T13:09:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTQ5OSM2NzgwOTk1IzIwMjAyMjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTQ5OSM2NzgwOTk1IzIwMjAyMjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/819122","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=819122"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/819122\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=819122"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=819122"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=819122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}